Prinzmetal Angina in a Young Patient with Essential Thrombocythemia, After Anagrelide Initiation - Case Report and Literature Review

1. Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA: a cancer journal for clinicians. 2009 May 1;59(3):171-91.DOI: 10.3322/caac.20009.10.3322/caac.2000919369682Open DOISearch in Google Scholar

2. De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Micò C, Tieghi A, Cacciola RR, Santoro C, Gerli G. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. haematologica. 2008 Mar 1;93(3):372-80. DOI: 10.3324/haematol.1205310.3324/haematol.1205318268279Open DOISearch in Google Scholar

3. Gugliotta L, Tieghi A, Tortorella G, Scalzulli PR, Ciancia R, Lunghi M, Cacciola E, Cacciola R, Candoni A, Crugnola M, Codeluppi K. Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia. Leukemia research. 2011 Dec 1;35(12):1557-63. DOI: https://doi.org/10.1016/j.leukres.2011.06.030.10.1016/j.leukres.2011.06.03021764130Open DOISearch in Google Scholar

4. Mazzucconi MG, Redi RO, Bernasconi SA, Bizzoni L, Dragoni FR, Latagliata R, Santoro CR, Mandelli FR. A long-term study of young patients with essential thrombocythemia treated with anagrelide. Haematologica. 2004 Jan 1;89(11):1306-13.Search in Google Scholar

5. Jurgens DJ, Moreno-Aspitia A, Tefferi A. Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia. Haematologica. 2004 Jan 1;89(11):1394-5.10.1182/blood.V104.11.1515.1515Search in Google Scholar

6. Proietti R, Rognoni A, Ardizzone F, Maccio S, Santagostino A, Rognoni G. Atypical Takotsubo syndrome during anagrelide therapy. Journal of Cardiovascular Medicine. 2009 Jul 1;10(7):546-9. DOI: 10.2459/JCM.0b013e32832b7f08.10.2459/JCM.0b013e32832b7f0819395976Search in Google Scholar

7. Lim YH, Lee YY, Kim JH, Shin J, Lee JU, Kim KS, Kim SK, Kim JH, Lim HK. Development of acute myocardial infarction in a young female patient with essential thrombocythemia treated with anagrelide: a case report. The Korean journal of hematology. 2010 Jun 1;45(2):136-8. DOI: 10.5045/kjh.2010.45.2.136.10.5045/kjh.2010.45.2.136298303021120194Open DOISearch in Google Scholar

8. Teffer A. Diagnosis and clinical manifestations of essential thrombocythemia [Internet]. Uptodate.com. 2012 [cited May 2017]. Available from: https://www.uptodate.com/contents/diagnosisand-clinical-manifestations-of-essentialthrombocythemia?search=Diagnosis%20and%20clinical%20manifestations%20of%20essential%20thromboc-ythemia&source=search_result&selectedTitle=1~57&usage_type=default&display_rank=1.Search in Google Scholar

9. Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. InSeminars in thrombosis and hemostasis 2007 Jun (Vol. 33, No. 04, pp. 313-320). Copyright© 2007 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.. DOI:10.1055/s-2007-976165.10.1055/s-2007-97616517525888Open DOISearch in Google Scholar

10. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, Orlandi E, Arcaini L, Brusamolino E, Pascutto C, Cazzola M. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. The American journal of medicine. 2004 Nov 15;117(10):755-61. DOI:10.1016/j.amjmed.2004.06.03210.1016/j.amjmed.2004.06.03215541325Search in Google Scholar

11. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. InMayo Clinic Proceedings 2006 Feb 1 (Vol. 81, No. 2, pp. 159-166). Elsevier. DOI:10.4065/81.2.159.10.4065/81.2.15916471068Open DOISearch in Google Scholar

12. Bleeker JS, Hogan WJ. Thrombocytosis: Diagnostic Evaluation, Thrombotic Risk Stratification, and Risk-Based Management Strategies. Thrombosis. 2011;2011:16. http://dx.doi.org/10.1155/2011/536062.10.1155/2011/536062320028222084665Open DOISearch in Google Scholar

13. Barbui T, Finazzi MC, Finazzi G. Frontline therapy in polycythemia vera and essential thrombocythemia. Blood reviews. 2012 Sep 1;26(5):205-11. DOI: 10.1016/j.blre.2012.06.002.10.1016/j.blre.2012.06.002Open DOISearch in Google Scholar

14. Emadi A, Spivak JL. Anagrelide: 20 years later. Expert review of anticancer therapy. 2009 Jan 1;9(1):37-50. DOI: 10.1586/14737140.9.1.37.10.1586/14737140.9.1.37Open DOISearch in Google Scholar

15. Fruchtman SM, Petitt RM, Gilbert HS, Fiddler G, Lyne A. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leukemia research. 2005 May 1;29(5):481-91. DOI:10.1016/j.leukres.2004.10.002.10.1016/j.leukres.2004.10.002Open DOISearch in Google Scholar

16. Tomer A. Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. Blood. 2002 Mar 1;99(5):1602-9. DOI: https://doi.org/10.1182/blood.V99.5.1602.10.1182/.V99.5.1602Open DOISearch in Google Scholar

17. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood. 2001 Feb 15;97(4):863-6. DOI: 10.1182/blood. V97.4.863.10.1182/.V97.4.863Open DOISearch in Google Scholar

18. Anagrelide. Drug Information. UpToDate 2012Retrieved December 11, 2017 from www.UpToDate.com, version 17.3.Search in Google Scholar

19. Lin GM, Chao TY, Wang WB. Acute coronary syndromes and Anagrelide. International journal of cardiology. 2007 Apr 12;117(1):e17-9. DOI:10.1016/j.ijcard.2006.07.079.10.1016/j.ijcard.2006.07.079Open DOISearch in Google Scholar

20. Kumagai N, Mitsutake R, Miura SI, Kawamura A, Takamiya Y, Nishikawa H, Uehara Y, Saku K. Acute coronary syndrome associated with essential thrombocythemia. Journal of cardiology. 2009 Dec 1;54(3):485-9. doi: 10.1016/j.jjcc.2009.03.001.10.1016/j.jjcc.2009.03.001Open DOISearch in Google Scholar

21. Watanabe T, Fujinaga H, Ikeda Y, Higashi T, Murakami M, Kawahara K, Hayashi I, Niki T, Shigekiyo T, Wakatsuki T. Acute myocardial infarction in a patient with essential thrombocythemia who underwent successful stenting: a case report. Angiology. 2005 Nov;56(6):771-4. DOI:10.1177/000331970505600616.10.1177/000331970505600616Open DOISearch in Google Scholar

22. Fujimura M, Akaike M, Kato M, Takamori N, Abe M, Nishiuchi T, Azuma H, Matsumoto T. Aggressive antiplatelet therapy before coronary stent implantation in acute coronary syndrome with essential thrombocythemia: a case report. Angiology. 2003 Jul;54(4):485-90. DOI:10.1177/000331970305400414.10.1177/000331970305400414Open DOISearch in Google Scholar

23. Turgut T, Harjai KJ, Edupuganti R, Cole J, Jenkins JS, Ramee SR, Collins TJ. Acute coronary occlusion and in‐stent thrombosis in a patient with essential thrombocythemia. Catheterization and Cardiovascular Interventions. 1998 Dec 1;45(4):428-33. DOI:10.1002/(SICI)1097-0304(199812)45:4<428::AIDCCD19> 3.0.CO;2-E.10.1002/(SICI)1097-0304(199812)45:4<428::AIDCCD19>3.0.CO;2-Open DOISearch in Google Scholar

24. Ozben B, Ekmekci A, Bugra Z, Umman S, Meric M. Multiple coronary thrombosis and stent implantation to the subtotally occluded right renal artery in a patient with essential thrombocytosis: a case report with review. Journal of thrombosis and thrombolysis. 2006 Aug 1;22(1):79-84. DOI:10.1007/s11239-006-7790-8.10.1007/s11239-006-7790-8Open DOISearch in Google Scholar

25. Daya SK, Gowda RM, Landis WA, Khan IA. Essential thrombocythemia-related acute ST-segment elevation myocardial infarction: A case report and literature review. Angiology. 2004 May;55(3):319-23. DOI:10.1177/000331970405500312.10.1177/000331970405500312Open DOISearch in Google Scholar

26. Koh KK, Cho SK, Kim SS, Oh BH, Lee YW. Coronary vasospasm, multiple coronary thrombosis, unstable angina and essential thrombocytosis. International journal of cardiology. 1993 Sep 1;41(2):168-70. DOI: https://doi.org/10.1016/0167-5273(93)90158-D.10.1016/0167-5273(93)90158-Open DOISearch in Google Scholar

27. Choi HS, Jeong MH, Seo IK, Lee MG, Ko JS, Park KH, Sim DS, Yoon NS, Kim KH, Park HW, Hong YJ. Very late stent thrombosis in a drug-eluting stent due to interruption of anti-platelet agents in patients with acute myocardial infarction and thrombocytosis. Korean circulation journal. 2011 Jul 1;41(7):417-20. doi: 10.4070/kcj.2011.41.7.417.10.4070/kcj.2011.41.7.417Open DOISearch in Google Scholar

28. Rugină M, Predescu L, Molfea V, Coman IM, Bubenek-Turconi Ş. Afectarea cardiacă în cadrul trombocitemiei esenţiale--review. Romanian Journal of Cardiology. 2011 Sep 1;21(3).Search in Google Scholar

29. Nardi F, Verna E, Secco GG, Rognoni A, Bongo AS, Iraghi G, Bertuol S, Lupi A. Variant angina associated with coronary artery endothelial dysfunction and myocardial bridge: a case report and review of the literature. Internal Medicine. 2011;50(21):2601-6. DOI:https://doi.org/10.2169/internalmedicine.50.6086.10.2169/internalmedicine.50.6086Open DOISearch in Google Scholar

30. Chahine RA, Raizner AE, Ishimori T. The clinical significance of exerciseinduced ST-segment elevation. Circulation. 1976;54(2):209-13. DOI: https://doi.org/10.1161/01.CIR.54.2.20910.1161/01.CIR.54.2.209Open DOISearch in Google Scholar

31. Gallik DM, Mahmarian JJ, Verani MS. Therapeutic significance of exerciseinduced ST-segment elevation in patients without previous myocardial infarction. The American journal of cardiology. 1993;72(1):1-7. DOI: https://doi.org/10.1016/0002-9149(93)90209-U.10.1016/0002-9149(93)90209-Open DOISearch in Google Scholar

32. Testa-Fernández A, Rios-Vazquez R, Sieira-Rodríguez-Moret J, Franco-Gutierrez R, Peña-Gil C, Pérez-Fernández R, Puebla-Rojo V, Regueiro-Abel M, Gonzalez-Juanatey C. “Giant R wave” electrocardiogram pattern during exercise treadmill test: A case report. Journal of medical case reports. 2011 Dec;5(1):304. DOI: 10.1186/1752-1947-5-304.10.1186/1752-1947-5-304316254021745406Open DOISearch in Google Scholar

33. Hung MJ. Current advances in the understanding of coronary vasospasm. World journal of cardiology. 2010 Feb 26;2(2):34-42.DOI: 10.4330/wjc.v2.i2.34.10.4330/wjc.v2.i2.34299886621160682Open DOISearch in Google Scholar

34. Shin DI, Horlitz M, Haltern G, Krölls W, Coll M, Bufe A, Lapp H, Gülker H. Therapieoptionen einer Prinzmetal-Angina induzierten ventrikulären Vulnerabilität. Zeitschrift für Kardiologie. 2003 Apr 1;92(4):332-8. DOI:10.1007/s00392-003-0916-5.10.1007/s00392-003-0916-512707793Search in Google Scholar

35. Maeder M, Ammann P, Angehrn W, Rickli H. A case of coronary vasospasm treated with stent placement. Zeitschrift fur Kardiologie. 2003 Feb;92(2):182-7. DOI:10.1007/s00392-003-0882-y.10.1007/s00392-003-0882-yOpen DOISearch in Google Scholar

36. Tanabe Y, Itoh E, Suzuki K, Ito M, Hosaka Y, Nakagawa I, Kumakura M. Limited role of coronary angioplasty and stentingin coronary spastic angina with organic stenosis. Journal of the American College of Cardiology. 2002 Apr 3;39(7):1120-6. DOI:https://doi.org/10.1016/S0735-1097(02)01746-1.10.1016/S0735-1097(02)01746-1Open DOISearch in Google Scholar

37. JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary Spastic Angina)(JCS 2013). Circulation Journal. 2014 Oct 24;78(11):2779-801. DOI: 10.1253/circj.CJ-66-0098.10.1253/circj.CJ-66-0098Open DOISearch in Google Scholar

38. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP. Authors/Task Force members. 2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014 Oct 1;35(37):2541-619.DOI:10.1093/eurheartj/ehu278.10.1093/eurheartj/ehu27825173339Open DOISearch in Google Scholar

39. Gaetano A, Crea F. Vasospastic angina [Internet]. Escardio.org. 2013 [cited 12 January 2018]. Available from: https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-2/Vasospastic-Angina-Title-Vasospastic-AnginaSearch in Google Scholar

40. Wong RS, Lam LW, Cheng G. Successful rechallenge with anagrelide in a patient with anagrelide-associated cardiomyopathy. Annals of hematology. 2008 Aug 1;87(8):683-4. DOI: 10.1007/s00277-008-0451-6.10.1007/s00277-008-0451-618299832Search in Google Scholar

41. Nakamura MO, Takeshita A, Nose Y. Clinical characteristics associated with myocardial infarction, arrhythmias, and sudden death in patients with vasospastic angina. Circulation. 1987 Jun 1;75(6):1110-6. DOI: https://doi.org/10.1161/01.CIR.75.6.1110.10.1161/01.CIR.75.6.11103568322Open DOISearch in Google Scholar

42. Dresen WF, Wells QS, Maron DJ, McPherson JA. Therapeutic procedures for coronary vasospasm-induced polymorphic ventricular tachycardia. Therapeutic advances in cardiovascular disease. 2012 Jun;6(3):115-21. DOI: 10.1177/1753944712446303.10.1177/175394471244630322547691Open DOISearch in Google Scholar

43. Matsue Y, Suzuki M, Nishizaki M & al. Clinical implications of an implantable cardioverterdefibrillator in patients with vasospastic angina and lethal ventricular arrhythmia. J Am Coll Cardiol. 2012; 60(10):908-913. DOI: 10.1016/j.jacc.2012.03.070.10.1016/j.jacc.2012.03.07022840527Search in Google Scholar